Asset Details
Do you wish to reserve the book?
Clinical activity of arsenic trioxide for the treatment of multiple myeloma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical activity of arsenic trioxide for the treatment of multiple myeloma
Do you wish to request the book?
Clinical activity of arsenic trioxide for the treatment of multiple myeloma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical activity of arsenic trioxide for the treatment of multiple myeloma
2002
Overview
Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, relapsed, and refractory acute promyelocytic leukemia (APL). Other investigators subsequently confirmed these results leading to approval of its use for relapsed or refractory APL in the United States. Investigations of this agent have demonstrated that its efficacy in APL and preclinical tumor models is dependent upon a number of mechanisms, including induction of apoptosis, effects on cellular differentiation, cell cycling, and tumor angiogenesis. Subsequent preclinical studies showed significant activity of arsenic trioxide in multiple myeloma (MM). Based on this, in a phase II trial, we have evaluated the activity of arsenic trioxide in 14 patients with relapsed MM, refractory to conventional salvage therapy. With the dose and schedule used, treatment with arsenic trioxide produced responses in three patients and prolonged stable disease in a fourth patient, with the longest response lasting 6 weeks. Although treatment was reasonably well tolerated, in these patients with extensive prior therapy, 11 developed cytopenia, five associated with infectious complications and three developed deep vein thromboses. The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM.
Publisher
Nature Publishing,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Arsenic
/ Arsenicals - adverse effects
/ Arsenicals - therapeutic use
/ Biological and medical sciences
/ Humans
/ Leukemia
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - pathology
/ Neoplasm Recurrence, Local - drug therapy
/ Neoplasm Recurrence, Local - pathology
/ Neutropenia - chemically induced
/ Patients
/ Pharmacology. Drug treatments
/ Tumors
